KR20240006575A - SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도 - Google Patents

SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도 Download PDF

Info

Publication number
KR20240006575A
KR20240006575A KR1020237040527A KR20237040527A KR20240006575A KR 20240006575 A KR20240006575 A KR 20240006575A KR 1020237040527 A KR1020237040527 A KR 1020237040527A KR 20237040527 A KR20237040527 A KR 20237040527A KR 20240006575 A KR20240006575 A KR 20240006575A
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040527A
Other languages
English (en)
Korean (ko)
Inventor
위고 무케
시릴 플랑셰
올리비에 슈바르츠
이그나시오 페르난데즈
티모시 브뤼엘
자비에 몬타구텔리
에르베 부리
드 멜로 길레르미 디아스
펠릭스 레이
Original Assignee
앵스띠뛰 파스퇴르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앵스띠뛰 파스퇴르 filed Critical 앵스띠뛰 파스퇴르
Publication of KR20240006575A publication Critical patent/KR20240006575A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237040527A 2021-04-26 2022-04-01 SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도 Pending KR20240006575A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IB2021000314 2021-04-26
IBPCT/IB2021/000314 2021-04-26
EP21306908 2021-12-22
EP21306908.1 2021-12-22
IB2022000108 2022-02-25
IBPCT/IB2022/000108 2022-02-25
PCT/EP2022/058777 WO2022228827A1 (en) 2021-04-26 2022-04-01 Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof

Publications (1)

Publication Number Publication Date
KR20240006575A true KR20240006575A (ko) 2024-01-15

Family

ID=81328034

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040527A Pending KR20240006575A (ko) 2021-04-26 2022-04-01 SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도

Country Status (5)

Country Link
US (1) US20240336672A1 (https=)
EP (1) EP4330278A1 (https=)
JP (1) JP2024518335A (https=)
KR (1) KR20240006575A (https=)
WO (1) WO2022228827A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061759A1 (en) * 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
CN120129695A (zh) * 2022-12-20 2025-06-10 北京昌平实验室 新型冠状病毒xbb.1.5及相关变异株广谱中和抗体及应用
CN120035605A (zh) * 2022-12-20 2025-05-23 北京昌平实验室 新型冠状病毒奥密克戎突变株广谱中和抗体及应用
EP4442276A1 (en) 2023-04-07 2024-10-09 Institut Pasteur Combined antibodies against sarbecoviruses and uses thereof
WO2025140539A1 (en) * 2023-12-29 2025-07-03 The University Of Hong Kong Ultrapotent broardly neutralizing antibodies against sars-cov-2 variants and methods of use thereof
WO2025153707A1 (en) 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
WO2025153835A1 (en) * 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP2755986A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
US9950065B2 (en) 2013-09-26 2018-04-24 Biontech Rna Pharmaceuticals Gmbh Particles comprising a shell with RNA
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
US10626400B2 (en) 2014-07-04 2020-04-21 Biontech Ag Stabilised formulations of RNA
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
SI3445850T1 (sl) 2016-04-22 2021-12-31 BioNTech SE Postopki za zagotavljanje enoverižne RNA
WO2018010815A1 (en) 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
KR20200109310A (ko) 2018-01-11 2020-09-22 비온테크 알엔에이 파마슈티컬스 게엠베하 Rna의 투여를 위한 제형
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
WO2021001023A1 (en) 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN111690059B (zh) * 2020-06-19 2022-03-08 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1D7
CN117003862B (zh) * 2020-08-19 2024-08-20 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111909260B (zh) * 2020-08-19 2022-06-21 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用

Also Published As

Publication number Publication date
WO2022228827A1 (en) 2022-11-03
US20240336672A1 (en) 2024-10-10
EP4330278A1 (en) 2024-03-06
JP2024518335A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
JP7684379B2 (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
KR20240006575A (ko) SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
KR102371300B1 (ko) 중동 호흡기 증후군-코로나바이러스 스파이크 단백질에 대한 인간 항체
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
DK2187964T3 (en) HIGH AFFINE HUMAN ANTIBODIES FOR HUMAN NERVOUS FACTOR
CN113354732B (zh) 针对埃博拉病毒糖蛋白的人抗体
KR102695416B1 (ko) 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법
AU2017345786B2 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
KR20230142790A (ko) 코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
US10450367B2 (en) Human antibodies against rabies and uses thereof
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
KR20230042598A (ko) SARS-CoV-2 중화 항체 또는 그 단편
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
KR20220054080A (ko) SARS-CoV-2 스파이크 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10435463B2 (en) Hepatitis C virus specific antibody
US20250320277A1 (en) Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
CN117836322A (zh) 针对SARS-CoV-2的人中和单克隆抗体及其用途
RU2779105C2 (ru) Антитела к респираторно-синцитиальному вирусу и способы их получения и применения
WO2023199943A1 (ja) コロナウイルス感染症を処置することに用いられる抗体
CN117715930A (zh) 抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250328

Comment text: Request for Examination of Application